Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care

被引：7

作者：

Bell, Jill A. ^{[1
]}

Galaznik, Aaron ^{[1
]}

Blazer, Marlo ^{[2
]}

Farrelly, Eileen ^{[2
]}

Ogbonnaya, Augustina ^{[2
]}

Raju, Aditya ^{[2
]}

Eaddy, Michael ^{[2
]}

Fram, Robert J. ^{[1
,2
]}

Faller, Douglas V. ^{[1
]}

机构：

[1] Millennium Pharmaceut Inc, Cambridge, MA USA

[2] Xcenda LLC, Palm Harbor, FL USA

来源：

LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 01期

关键词：

Higher-risk myelodysplastic syndrome; transfusion-free interval; survival; PROGNOSTIC SCORING SYSTEM; LEUKEMIA GROUP; PHASE-III; AZACITIDINE; IMPACT; MDS; CLASSIFICATION; DECITABINE; CANCER; LIFE;

D O I：

10.1080/10428194.2018.1464155

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Most higher-risk myelodysplastic syndrome (HR-MDS) patients will become transfusion-dependent, leading to potential complications, including infections or end-organ dysfunction. Data correlating achievement of transfusion-free intervals (TFIs) during first-line therapy (1LT) with survival are sparse. We evaluated HR-MDS patients receiving 1LT diagnosed from 1/1/2008 to 7/31/2015 and the impact of a TFI (>= 60-day interval without transfusions) on progression-free and overall survival (PFS, OS) using Cox proportional-hazard models. Two hundred and twenty-nine HR-MDS patients received 1LT; overall, median PFS/OS were 8.4 months and 14.7 months, respectively. Two-year PFS/OS were 22.3% and 34.6%, respectively. Median PFS/OS were longer for patients with vs. without a TFI (16.9 vs. 6.1 months and 26.1 vs. 11.8 months, respectively; p < .01 [both]). Two-year PFS (43.0% vs. 3.9%; p < .01) and 2-year OS (51.8% vs. 22.5%; p < .01) were also longer in patients with a TFI vs. not. Achievement of a TFI during 1LT appears to positively affect PFS and OS in HR-MDS patients.

引用

页码：49 / 59

页数：11

共 27 条

[11] Revised International Prognostic Scoring System for Myelodysplastic Syndromes [J].

Greenberg, Peter L. ;

Tuechler, Heinz ;

Schanz, Julie ;

Sanz, Guillermo ;

Garcia-Manero, Guillermo ;

Sole, Francesc ;

Bennett, John M. ;

Bowen, David ;

Fenaux, Pierre ;

Dreyfus, Francois ;

Kantarjian, Hagop ;

Kuendgen, Andrea ;

Levis, Alessandro ;

Malcovati, Luca ;

Cazzola, Mario ;

Cermak, Jaroslav ;

Fonatsch, Christa ;

Le Beau, Michelle M. ;

Slovak, Marilyn L. ;

Krieger, Otto ;

Luebbert, Michael ;

Maciejewski, Jaroslaw ;

Magalhaes, Silvia M. M. ;

Miyazaki, Yasushi ;

Pfeilstoecker, Michael ;

Sekeres, Mikkael ;

Sperr, Wolfgang R. ;

Stauder, Reinhard ;

Tauro, Sudhir ;

Valent, Peter ;

Vallespi, Teresa ;

van de Loosdrecht, Arjan A. ;

Germing, Ulrich ;

Haase, Detlef .

BLOOD, 2012, 120 (12) :2454-2465

[12] Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications [J].

Gupta, P ;

LeRoy, SC ;

Luikart, SD ;

Bateman, A ;

Morrison, VA .

LEUKEMIA RESEARCH, 1999, 23 (10) :953-959

[13] Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis [J].

Harnan, Sue ;

Ren, Shiji ;

Gomersall, Tim ;

Everson-Hock, Emma S. ;

Sutton, Anthea ;

Dhanasiri, Sujith ;

Kulasekararaj, Austin .

ACTA HAEMATOLOGICA, 2016, 136 (01) :23-42

[14] Management of anemia associated with myelodysplastic syndrome [J].

Hellström-Lindberg, E .

SEMINARS IN HEMATOLOGY, 2005, 42 (02) :S10-S13

[15] Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents [J].

Jabbour, Elias ;

Strati, Paolo ;

Cabrero, Monica ;

O'Brien, Susan ;

Ravandi, Farhad ;

Bueso-Ramos, Carlos ;

Wei, Qiao ;

Hu, Jianhua ;

Abi Aad, Simon ;

Short, Nicholas J. ;

Dinardo, Courtney ;

Daver, Naval ;

Kadia, Tapan ;

Wierda, William ;

Wei, Yue ;

Colla, Simona ;

Borthakur, Gautam ;

Cortes, Jorge ;

Estrov, Zeev ;

Kantarjian, Hagop ;

Garcia-Manero, Guillermo .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (04) :351-358

[16] Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study [J].

Kantarjian, H ;

Issa, JPJ ;

Rosenfeld, CS ;

Bennett, JM ;

Albitar, M ;

DiPersio, J ;

Klimek, V ;

Slack, J ;

de Castro, C ;

Ravandi, F ;

Helmer, R ;

Shen, LL ;

Nimer, SD ;

Leavitt, R ;

Raza, A ;

Saba, H .

CANCER, 2006, 106 (08) :1794-1803

[17] Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes [J].

Komrokji, Rami S. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 :S39-S43

[18]

Lawrence Louann W, 2004, Clin Lab Sci, V17, P178

[19] Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group [J].

Luebbert, Michael ;

Suciu, Stefan ;

Baila, Liliana ;

Ruter, Bjorn Hans ;

Platzbecker, Uwe ;

Giagounidis, Aristoteles ;

Selleslag, Dominik ;

Labar, Boris ;

Germing, Ulrich ;

Salih, Helmut R. ;

Beeldens, Filip ;

Muus, Petra ;

Pfluger, Karl-Heinz ;

Coens, Corneel ;

Hagemeijer, Anne ;

Schaefer, Hans Eckart ;

Ganser, Arnold ;

Aul, Carlo ;

de Witte, Theo ;

Wijermans, Pierre W. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) :1987-1996

[20] Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes [J].

Lyons, Roger M. ;

Cosgriff, Thomas M. ;

Modi, Sanjiv S. ;

Gersh, Robert H. ;

Hainsworth, John D. ;

Cohn, Allen L. ;

McIntyre, Heidi J. ;

Fernando, Indra J. ;

Backstrom, Jay T. ;

Beach, C. L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1850-1856

← 1 2 3 →